TYK2 inhibitor Promising for Psoriasis in Phase 3 Studies

by admin | Mar 31, 2026 | Health

Spread the love

A TYK2 inhibitor in development shows superior efficacy to placebo and apremilast for treating psoriasis, with no new safety concerns emerging.
Medscape Medical News

← TYK2 inhibitor Promising for Psoriasis in Phase 3 Studies With the Indo-Pacific concept’s demise, what of Japan, Australia? →

Written By

Written by Albert Pham, News Curator and Blogger

McDonald’s Chicken and Beverage Strategy: Global Growth Plans Through 2030

Oct 12, 2026 | albertpham, Economy_finances, Health

McDonald’s is expanding its chicken menu and specialty beverages to gain market share by 2030, challenge competitors and attract more customers.

Endometriosis in Canada: Why Women Are Seeking Treatment in Mexico

Oct 12, 2026 | albertpham, Health, Travel

Canadian women are travelling to Mexico for endometriosis treatment after facing long wait times, highlighting gaps in specialist care and women’s health services.

Type 2 Diabetes Symptoms: 5 Early Warning Signs to Know

Oct 12, 2026 | albertpham, Health

Frequent thirst, fatigue, blurred vision and unexplained weight changes may signal type 2 diabetes. Learn the warning signs and when to seek medical advice.

TYK2 inhibitor Promising for Psoriasis in Phase 3 Studies

Written By

Related Posts

McDonald’s Chicken and Beverage Strategy: Global Growth Plans Through 2030

Endometriosis in Canada: Why Women Are Seeking Treatment in Mexico

Type 2 Diabetes Symptoms: 5 Early Warning Signs to Know

0 Comments

Explore More

Connect With Us

Quick Links

Legal

Stay Updated